Farmakal Health Care Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 0.20 M
- Company Age 17 Year, 27 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.00 M
- Revenue Growth 63.92%
- Profit Growth 107.55%
- Ebitda 689.23%
- Net Worth 16.91%
- Total Assets -16.64%
About Farmakal Health Care
Farmakal Health Care Private Limited (FHCPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 18 January 2008 and has a history of 17 years. Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹2.00 M.
Kavita Desai, Rahul Bisht, Sangeeta Desai, and One other member serve as directors at the Company.
Company Details
-
Location
Indore, Madhya Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232MP2008PTC020228
-
Company No.
020228
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
18 Jan 2008
-
Date of AGM
21 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Farmakal Health Care?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kavita Desai
|
Director | 25-Oct-2013 | Current |
|
Rahul Bisht
|
Director | 30-Sep-2013 | Current |
|
Sangeeta Desai
|
Director | 18-Jan-2008 | Current |
|
Shailesh Desai
|
Director | 18-Jan-2008 | Current |
Financial Performance of Farmakal Health Care.
Farmakal Health Care Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 63.92% increase. The company also saw a substantial improvement in profitability, with a 107.55% increase in profit. The company's net worth Soared by an impressive increase of 16.91%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Farmakal Health Care?
In 2018, Farmakal Health Care had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.00 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Dec 2021 | Hdfc Bank Limited | ₹2.00 M | Open |
How Many Employees Work at Farmakal Health Care?
Unlock and access historical data on people associated with Farmakal Health Care, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Farmakal Health Care, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Farmakal Health Care's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.